Syndax Pharmaceuticals announced the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5. Sabus brings to Syndax more than 30 years of commercial experience launching drugs and building sales and marketing organizations within the biopharmaceutical industry. As Chief Commercial Officer, Sabus will oversee all commercial functions, including the development of critical launch initiatives, sales planning and commercial strategy. Prior to joining Syndax, Sabus served as Chief Commercial Officer at Turning Point Therapeutics, before being acquired by BMS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly